G. Lingas

发表

Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs

Mark S. Anderson, Chun Jimmie Ye, Gabriela K. Fragiadakis, 2022, Science immunology.

The value of open-source clinical science in pandemic response: lessons from ISARIC

Siti Zubaidah Othman, Karl Erik Müller, Jose M. Mandei, 2021, The Lancet Infectious Diseases.

Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model

X. de Lamballerie, G. Moureau, B. Coutard, 2020, Nature Communications.

Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives

Inserm, Shana M Augustin, C. Charpentier, 2020, Clinical Microbiology and Infection.

Respiratory support in patients with severe COVID-19 in the International Severe Acute Respiratory and Emerging Infection (ISARIC) COVID-19 study: a prospective, multinational, observational study

C. A. Shaw, Eglantine Ferrand Devouge, Su Hwan Lee, 2022, Critical Care.

Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial

R. Greil, Y. Yazdanpanah, D. Costagliola, 2022, The Journal of antimicrobial chemotherapy.

Oropharyngeal and intestinal concentrations of opportunistic pathogens are independently associated with death of SARS-CoV-2 critically ill adults

C. Charpentier, J. Timsit, J. Hulot, 2022, Critical Care.

Symptom‐based case definitions for COVID‐19: Time and geographical variations for detection at hospital admission among 260,000 patients

Siti Zubaidah Othman, Eyvind W. Axelsen, C. A. Shaw, 2022, Influenza and other respiratory viruses.

Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates

P. Roques, V. Contreras, S. van der Werf, 2022, Nature Communications.

Modeling remdesivir antiviral efficacy in COVID-19 hospitalized patients of the randomized, controlled, open-label DisCoVeRy trial

R. Greil, Y. Yazdanpanah, D. Costagliola, 2021, medRxiv.

Favipiravir and severe acute respiratory syndrome coronavirus 2 in hamster model

G. Moureau, B. Coutard, F. Touret, 2020, bioRxiv.

Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort

Y. Yazdanpanah, J. Timsit, F. Raffi, 2021, Proceedings of the National Academy of Sciences.

Lassa viral dynamics in non-human primates treated with favipiravir or ribavirin

K. Rosenke, D. Safronetz, J. Guedj, 2021, PLoS Comput. Biol..

Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

Andrew J. Oler, Eglantine Ferrand Devouge, P. Gregersen, 2023, Genome Medicine.

COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study

Karl Erik Müller, Jose M. Mandei, C. A. Shaw, 2021, Infection.

Survival of SARS-CoV-2 on Non-Porous Materials in an Experimental Setting Representative of Fomites

J. Lucet, J. Guedj, B. Muylkens, 2021, Coatings.

Chronic use of renin‐angiotensin‐aldosterone system blockers and mortality in COVID‐19: A multicenter prospective cohort and literature review

V. Gaborieau, A. Sommet, R. Favory, 2021, Fundamental & clinical pharmacology.

Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

Andrew J. Oler, Eglantine Ferrand Devouge, P. Gregersen, 2023, Genome Medicine.

Association of Country Income Level With the Characteristics and Outcomes of Critically Ill Patients Hospitalized With Acute Kidney Injury and COVID-19

Siti Zubaidah Othman, C. A. Shaw, Eglantine Ferrand Devouge, 2023, Kidney International Reports.

Modelling the association between neutralizing antibody levels and SARS-CoV-2 viral dynamics : implications to define correlates of protection against infection

C. Delaugerre, D. Duffy, O. Schwartz, 2023, medRxiv.

Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths

Mark S. Anderson, P. Gregersen, R. Nussbaum, 2021, Science Immunology.

Neutrophil Activation and Immune Thrombosis Profiles Persist in Convalescent COVID-19

C. Charpentier, J. Timsit, J. Hulot, 2023, Journal of Clinical Immunology.

Symptom‐based case definitions for COVID‐19: Time and geographical variations for detection at hospital admission among 260,000 patients

Siti Zubaidah Othman, Eyvind W. Axelsen, C. A. Shaw, 2022, Influenza and other respiratory viruses.

Neutralizing Antibody Levels as a Correlate of Protection Against SARS‐CoV‐2 Infection: A Modeling Analysis

S. Kernéis, D. Duffy, J. Hadjadj, 2023, Clinical pharmacology and therapeutics.

Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs

Mark S. Anderson, Chun Jimmie Ye, P. Gregersen, 2022, Science Immunology.